Zentalis Pharmaceuticals, Inc. (ZNTL)
NASDAQ: ZNTL · Real-Time Price · USD
4.040
+0.250 (6.60%)
At close: Jun 26, 2026, 4:00 PM EDT
4.050
+0.010 (0.25%)
After-hours: Jun 26, 2026, 7:39 PM EDT
Zentalis Pharmaceuticals Employees
Zentalis Pharmaceuticals had 106 employees as of December 31, 2025. The number of employees decreased by 60 or -36.14% compared to the previous year.
Employees
106
Change (1Y)
-60
Growth (1Y)
-36.14%
Revenue / Employee
n/a
Profits / Employee
-$1,171,066
Market Cap
287.59M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Bicycle Therapeutics | 288 |
| Entrada Therapeutics | 152 |
| Adagene | 128 |
| SAB Biotherapeutics | 86 |
| Cartesian Therapeutics | 75 |
| InflaRx | 65 |
| Surrozen | 44 |
| ALX Oncology Holdings | 43 |
ZNTL News
- 13 days ago - Zentalis assumed with an Outperform at Oppenheimer - TheFly
- 24 days ago - Zentalis Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 26 days ago - Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Zentalis Strengthens Commercial Leadership with Appointments of Shannon Campbell to Board of Directors and Sarah Kelly as SVP of Commercial Strategy - GlobeNewsWire
- 4 weeks ago - Zentalis Pharmaceuticals Proxy statement: Proxy filing - Filings
- 4 weeks ago - Zentalis Pharmaceuticals Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA - Transcripts
- 5 weeks ago - Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026 - GlobeNewsWire
- 5 weeks ago - Zentalis Pharmaceuticals Transcript: Stifel 2026 Targeted Oncology Virtual Forum - Transcripts